UroGen Pharma Ltd. (URGN): debt financing — UroGen Pharma secures up to $250M loan at 8.25%; $200M funded to refinance existing debt

UroGen Pharma Ltd.

Tranche A of $200M funded on Feb 26, used to refinance $125M existing term loan and fund working capital.
Loan bears fixed 8.25% interest quarterly; principal repayments start Q1 2030 in four equal quarterly installments.
Second tranche of $50M available upon election by June 30, 2027, subject to conditions.
No financial covenants; collateral includes substantially all assets including intellectual property.
Loan matures 5 years from closing; prepayment subject to exit fee of 1% and makewhole within first year.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.99

UroGen Pharma Ltd. incurred term loan of up to $250,000,000, to be advanced in two tranches; Tranche A Loan of $200,000,000 funded; Tranche B Loan of $50,000,000 with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC at 8.25% per annum fixed maturing 5th year anniversary of the Tranche A Closing Date.

Instrument: term loan
Principal: up to $250,000,000, to be advanced in two tranches; Tranche A Loan of $200,000,000 funded; Tranche B Loan of $50,000,000
Counterparty: BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC
Rate: 8.25% per annum fixed
Maturity: 5th year anniversary of the Tranche A Closing Date
Event: incurrence

Exact text from the filing

On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $250,000,000, to be advanced in two tranches (the “Term Loans”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

UroGen Pharma Ltd. entered into Loan Agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC valued at up to $250,000,000 (effective 2026-02-26).

Action: entry
Agreement: credit facility
Counterparty: BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC
Value: up to $250,000,000
Effective: 2026-02-26

Exact text from the filing

On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $250,000,000, to be advanced in two tranches (the “Term Loans”).

View on SEC.gov

Browse all debt financings →

UroGen Pharma Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-26-084282

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.